Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · IEX Real-Time Price · USD
0.759
+0.007 (0.89%)
At close: May 1, 2024, 4:00 PM
0.770
+0.011 (1.50%)
After-hours: May 1, 2024, 7:33 PM EDT
Cara Therapeutics Revenue
In the year 2023, Cara Therapeutics had annual revenue of $20.97M, a decrease of -49.92%. Revenue in the quarter ending December 31, 2023 was $3.00M, a -7.88% decrease year-over-year.
Revenue (ttm)
$20.97M
Revenue Growth
-49.92%
P/S Ratio
1.98
Revenue / Employee
$381,236
Employees
55
Market Cap
41.47M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.97M | -20.90M | -49.92% |
Dec 31, 2022 | 41.87M | 18.84M | 81.81% |
Dec 31, 2021 | 23.03M | -112.05M | -82.95% |
Dec 31, 2020 | 135.08M | 115.20M | 579.28% |
Dec 31, 2019 | 19.89M | 6.42M | 47.64% |
Dec 31, 2018 | 13.47M | 12.56M | 1,378.49% |
Dec 31, 2017 | 911.00K | 825.00K | 959.30% |
Dec 31, 2016 | 86.00K | -3.72M | -97.74% |
Dec 31, 2015 | 3.80M | 626.00K | 19.70% |
Dec 31, 2014 | 3.18M | -8.79M | -73.45% |
Dec 31, 2013 | 11.96M | 10.77M | 905.38% |
Dec 31, 2012 | 1.19M | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Rapid Micro Biosystems | 22.52M |
Ocuphire Pharma | 19.05M |
ImmuCell | 17.47M |
iCAD, Inc. | 17.32M |
ReWalk Robotics | 13.85M |
Aspira Women's Health | 9.15M |
Cyclo Therapeutics | 1.08M |
CARA News
- 4 weeks ago - Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference - MarijuanaStocks
- 4 weeks ago - Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 - GlobeNewsWire
- 2 months ago - Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 - GlobeNewsWire
- 3 months ago - Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026 - GlobeNewsWire
- 4 months ago - Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis - GlobeNewsWire
- 6 months ago - Cara Therapeutics Reports Third Quarter 2023 Financial Results - GlobeNewsWire